Comparison of First-Line Dual Combination Treatments in Hypertension: Real-World Evidence from Multinational Heterogeneous Cohorts
Korean Circulation Journal
;
: 52-68, 2020.
Article
in English
| WPRIM
| ID: wpr-786211
ABSTRACT
BACKGROUND AND OBJECTIVES:
2018 ESC/ESH Hypertension guideline recommends 2-drug combination as initial anti-hypertensive therapy. However, real-world evidence for effectiveness of recommended regimens remains limited. We aimed to compare the effectiveness of first-line anti-hypertensive treatment combining 2 out of the following classes angiotensin-converting enzyme (ACE) inhibitors/angiotensin-receptor blocker (A), calcium channel blocker (C), and thiazide-type diuretics (D).METHODS:
Treatment-naïve hypertensive adults without cardiovascular disease (CVD) who initiated dual anti-hypertensive medications were identified in 5 databases from US and Korea. The patients were matched for each comparison set by large-scale propensity score matching. Primary endpoint was all-cause mortality. Myocardial infarction, heart failure, stroke, and major adverse cardiac and cerebrovascular events as a composite outcome comprised the secondary measure.RESULTS:
A total of 987,983 patients met the eligibility criteria. After matching, 222,686, 32,344, and 38,513 patients were allocated to A+C vs. A+D, C+D vs. A+C, and C+D vs. A+D comparison, respectively. There was no significant difference in the mortality during total of 1,806,077 person-years A+C vs. A+D (hazard ratio [HR], 1.08; 95% confidence interval [CI], 0.97−1.20; p=0.127), C+D vs. A+C (HR, 0.93; 95% CI, 0.87−1.01; p=0.067), and C+D vs. A+D (HR, 1.18; 95% CI, 0.95−1.47; p=0.104). A+C was associated with a slightly higher risk of heart failure (HR, 1.09; 95% CI, 1.01−1.18; p=0.040) and stroke (HR, 1.08; 95% CI, 1.01−1.17; p=0.040) than A+D.CONCLUSIONS:
There was no significant difference in mortality among A+C, A+D, and C+D combination treatment in patients without previous CVD. This finding was consistent across multi-national heterogeneous cohorts in real-world practice.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Calcium Channel Blockers
/
Calcium Channels
/
Cardiovascular Diseases
/
Cohort Studies
/
Mortality
/
Stroke
/
Diuretics
/
Propensity Score
/
Angiotensin Receptor Antagonists
/
Heart Failure
Type of study:
Etiology study
/
Practice guideline
/
Incidence study
/
Observational study
/
Prognostic study
Limits:
Adult
/
Humans
Country/Region as subject:
Asia
Language:
English
Journal:
Korean Circulation Journal
Year:
2020
Type:
Article
Similar
MEDLINE
...
LILACS
LIS